StreetAlpha.app
Home › Stocks › FDMT

4D Molecular Therapeutics, Inc. (FDMT)

Healthcare
$10.23
▼ −4.57%
LAST CLOSE · NOV 20

4D Molecular Therapeutics develops genetic medicines for eye diseases and cystic fibrosis, based in Emeryville, California. It last closed at $10.23 on Nov 20, down 4.57% on the day. The next earnings report for FDMT is expected around Wed, Mar 17, 2027, after the close. For the quarter ended Sep 2026, FDMT reported EPS of -$1.08 on revenue of $4.1M, with revenue up 4505.6% from a year ago. Over its last 8 reports the stock moved an average of 3.9% the session after earnings. Over the last 12 months FDMT insiders bought $0 of stock on the open market and sold $5.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is FDMT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FDMT.

Key Stats

Last 12 months
Results
Revenue
$96.1M
+79953.3% vs a year ago
Net income
−$200.4M
−208.6% margin
EPS (diluted)
−$2.70
Free cash flow
−$166.3M
−173.1% margin
Balance sheet
Cash & equivalents
$39.1M
At Sep 30
Debt
$19.7M
At Sep 30
Shareholder equity
$337.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.0M$18.0MFY2021FY2022: $3.1M$3.1MFY2022FY2023: $20.7M$20.7MFY2023FY2024: $37K$37KFY2024FY2025: $85.2M$85.2MFY2025

From FDMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 17
Estimated date · After the close
Reported EPS
-$1.08
Quarter ended Sep 2026
Year ago EPS
-$1.01
Same quarter last year
Revenue
$4.1M
+4505.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.90Dec '24Mar 2025: -$0.86Mar '25Jun 2025: -$0.98Jun '25Sep 2025: -$1.01Sep '25Dec 2025: $0.43Dec '25Mar 2026: -$1.01Mar '26Jun 2026: -$1.04Jun '26Sep 2026: -$1.08Sep '26Latest -$1.08
Revenue by quarter
Dec 2024: $1,000Dec '24Mar 2025: $14,000Mar '25Jun 2025: $15,000Jun '25Sep 2025: $90,000Sep '25Dec 2025: $85.1MDec '25Mar 2026: $3.0MMar '26Jun 2026: $3.8MJun '26Sep 2026: $4.1MSep '26Latest $4.1M
How FDMT moved after its last 8 reports
Average move the session after a report ±3.9%
Nov 12, 2026After the close+0.9%
Aug 13, 2026After the close+4.6%
May 7, 2026After the close+2.1%
Mar 18, 2026After the close+4.9%
Jan 7, 2026Time not announced+8.1%
Nov 6, 2025Time not announced+3.9%
Aug 11, 2025Time not announced−1.8%
May 8, 2025After the close−4.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on FDMTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on FDMT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on FDMT

Technical Analysis

FDMT · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 15% below its 20 day and 25% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $9.91, and the nearest resistance the Pivot at $10.43.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.9%/day
Key levels
$16.9352 week high+65.5%
$12.8050 day average+25.1%
$12.70100 day average+24.1%
$11.7720 day average+15.1%
$11.12200 day average+8.7%
$10.74Pivot R1+5.0%
$10.45Swing high (Jun 4)+2.2%
$10.43Pivot+2.0%
$10.23Last close
$9.91Pivot S1−3.1%
$9.39Swing low (Jul 29)−8.2%
$6.9652 week low−32.0%
Indicators
RSI (14)37.50Weak, oversold below 30Neutral
MACD-0.53Below its signal lineBearish
Stochastic8.4Near the bottom of its rangeOversold
ADX (14)15.4No clear trend
Williams %R-96.0Oversold below −80, overbought above −20Oversold
CCI (20)-147.8Oversold below −100, overbought above 100Oversold
Rate of change−16.5%Change over 10 sessionsBearish
ATR (14)$0.91Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FDMT

What happened before

See how FDMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow FDMT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How FDMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for FDMTHow many large options trades hit FDMT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

FDMT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲82 buying vs 61 selling
  • ●Shares held by funds +0.0%
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding167159+5.0%
In funds' top 1042+100.0%
Held by funds–––
New / increased28 / 5428 / 63−9.9%
Reduced / sold out43 / 1836 / 26−1.6%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FDMT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

FDMT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$5.3M17 sales · 3 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $21K2026-03 sold $3K2026-06 sold $1.4M2026-07 sold $737K2026-08 sold $1.5M2026-09 sold $841K2026-10 sold $775KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 16Scott BizilyChief Legal OfficerSale plan1,635$12.84$21K
Oct 5David KirnSee RemarksSale plan58,333$12.92$754K
Sep 16Scott BizilyChief Legal OfficerSale plan1,635$13.65$22K
Sep 14David KirnSee RemarksSale plan58,333$13.90$811K
Sep 1Scott BizilyChief Legal OfficerSale plan584$14.00$8K
Aug 19David KirnSee RemarksSale plan69,076$15.75$1.1M
Every insider buy and sale for FDMT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See FDMT insider trades →

From SEC Form 4 filings by FDMT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FDMT is in one of them and how their past FDMT trades turned out.

FDMT in the AI portfolios
Loading…

FDMT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FDMT in an article yet. Here's the latest on the wider market.

FDMT in the news

About 4D Molecular Therapeutics

4D Molecular Therapeutics is a biotechnology company that develops genetic medicines. Its product candidates use modified adeno-associated virus vectors, which are designed to carry therapeutic genes to target tissues. Its lead candidate is aimed at wet age-related macular degeneration and diabetic macular edema, two eye diseases, and is designed to be given by injection in a doctor's office. The company is also developing a treatment for lung disease in people with cystic fibrosis. It is based in Emeryville, California, and its intended customers are patients, eye and lung specialists, and healthcare payers.

Headquarters
Emeryville, CA